These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 39337557)

  • 1. Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation.
    Alfei S; Zuccari G; Athanassopoulos CM; Domenicotti C; Marengo B
    Int J Mol Sci; 2024 Sep; 25(18):. PubMed ID: 39337557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Remarkable and Selective In Vitro Cytotoxicity of Synthesized Bola-Amphiphilic Nanovesicles on Etoposide-Sensitive and -Resistant Neuroblastoma Cells.
    Alfei S; Giannoni P; Signorello MG; Torazza C; Zuccari G; Athanassopoulos CM; Domenicotti C; Marengo B
    Nanomaterials (Basel); 2024 Sep; 14(18):. PubMed ID: 39330662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesized
    Alfei S; Zuccari G; Bacchetti F; Torazza C; Milanese M; Siciliano C; Athanassopoulos CM; Piatti G; Schito AM
    Nanomaterials (Basel); 2024 Aug; 14(16):. PubMed ID: 39195389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma.
    Das I; Gad H; Bräutigam L; Pudelko L; Tuominen R; Höiom V; Almlöf I; Rajagopal V; Hansson J; Helleday T; Egyházi Brage S; Warpman Berglund U
    Cell Death Differ; 2020 Jul; 27(7):2081-2098. PubMed ID: 31919461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.
    Das I; Wilhelm M; Höiom V; Franco Marquez R; Costa Svedman F; Hansson J; Tuominen R; Egyhàzi Brage S
    Cell Death Dis; 2019 Sep; 10(9):663. PubMed ID: 31506424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer.
    Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ
    Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
    Lee SY; Cho HJ
    Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reverse transcriptase inhibition potentiates target therapy in BRAF-mutant melanomas: effects on cell proliferation, apoptosis, DNA-damage, ROS induction and mitochondrial membrane depolarization.
    Fattore L; Malpicci D; Milite C; Castellano S; Sbardella G; Botti G; Ascierto PA; Mancini R; Ciliberto G
    Cell Commun Signal; 2020 Sep; 18(1):150. PubMed ID: 32933538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
    Kaoud TS; Mohassab AM; Hassan HA; Yan C; Van Ravenstein SX; Abdelhamid D; Dalby KN; Abdel-Aziz M
    Eur J Med Chem; 2020 Jan; 186():111885. PubMed ID: 31784187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
    Szász I; Koroknai V; Kiss T; Vízkeleti L; Ádány R; Balázs M
    Melanoma Res; 2019 Aug; 29(4):390-400. PubMed ID: 30741840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.
    Blehm BH; Jiang N; Kotobuki Y; Tanner K
    Biomaterials; 2015 Jul; 56():129-39. PubMed ID: 25934286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiproliferative Imidazo-Pyrazole-Based Hydrogel: A Promising Approach for the Development of New Treatments for PLX-Resistant Melanoma.
    Alfei S; Milanese M; Brullo C; Valenti GE; Domenicotti C; Russo E; Marengo B
    Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of lactobionic acid based bola-amphiphiles and its application as nano-carrier for curcumin delivery to cancer cell cultures in-vitro.
    Habib SM; Jawad-Ur-Rehman ; Maharjan R; Kanwal T; Althagafi II; Saifullah S; Ullah S; Simjee SU; Shah MR
    Int J Pharm; 2020 Nov; 590():119897. PubMed ID: 32971176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyaluronated nanohydroxyapatite responsively released from injectable hydrogels for targeted therapy of melanoma.
    Chen H; Zhao M; Liu J; Xu R; Zou Y; Wang P; Tong L; Fan Y; Zhang X; Liang J; Sun Y
    Nanoscale; 2024 Jun; 16(24):11762-11773. PubMed ID: 38869001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative activity of vanadium compounds: effects on the major malignant melanoma molecular pathways.
    Pisano M; Arru C; Serra M; Galleri G; Sanna D; Garribba E; Palmieri G; Rozzo C
    Metallomics; 2019 Oct; 11(10):1687-1699. PubMed ID: 31490510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma.
    Charignon E; Bouché M; Clave-Darcissac C; Dahm G; Ichim G; Clotagatide A; Mertani HC; Telouk P; Caramel J; Diaz JJ; Bellemin-Laponnaz S; Bouvet P; Billotey C
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natural product mensacarcin induces mitochondrial toxicity and apoptosis in melanoma cells.
    Plitzko B; Kaweesa EN; Loesgen S
    J Biol Chem; 2017 Dec; 292(51):21102-21116. PubMed ID: 29074620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.